GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » InnovAge Holding Corp (NAS:INNV) » Definitions » Debt-to-EBITDA

InnovAge Holding (InnovAge Holding) Debt-to-EBITDA : 18.78 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is InnovAge Holding Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

InnovAge Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $12.0 Mil. InnovAge Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $100.4 Mil. InnovAge Holding's annualized EBITDA for the quarter that ended in Dec. 2023 was $6.0 Mil. InnovAge Holding's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 18.78.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for InnovAge Holding's Debt-to-EBITDA or its related term are showing as below:

INNV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -14.03   Med: 3.54   Max: 9.21
Current: -7.28

During the past 5 years, the highest Debt-to-EBITDA Ratio of InnovAge Holding was 9.21. The lowest was -14.03. And the median was 3.54.

INNV's Debt-to-EBITDA is ranked worse than
100% of 423 companies
in the Healthcare Providers & Services industry
Industry Median: 2.61 vs INNV: -7.28

InnovAge Holding Debt-to-EBITDA Historical Data

The historical data trend for InnovAge Holding's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnovAge Holding Debt-to-EBITDA Chart

InnovAge Holding Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-EBITDA
4.43 3.54 -14.03 9.21 -3.22

InnovAge Holding Quarterly Data
Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.79 -6.51 -3.96 -4.57 18.78

Competitive Comparison of InnovAge Holding's Debt-to-EBITDA

For the Medical Care Facilities subindustry, InnovAge Holding's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnovAge Holding's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, InnovAge Holding's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where InnovAge Holding's Debt-to-EBITDA falls into.



InnovAge Holding Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

InnovAge Holding's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(12.047 + 96.786) / -33.852
=-3.21

InnovAge Holding's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(12.037 + 100.416) / 5.988
=18.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


InnovAge Holding  (NAS:INNV) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


InnovAge Holding Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of InnovAge Holding's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


InnovAge Holding (InnovAge Holding) Business Description

Traded in Other Exchanges
N/A
Address
8950 East Lowry Boulevard, Denver, CO, USA, 80230
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.
Executives
Teresa Sparks director 40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Nicole Damato officer: CHIEF LEGAL OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Benjamin C Adams officer: CHIEF FINANCIAL OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Patricia Fontneau director 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Christine Bent officer: CHIEF OPERATIONS OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Thomas Scully director 320 PARK AVENUE, SUITE # 2500, NEW YORK NM 10022
Richard Feifer officer: CHIEF MEDICAL OFFICER C/O GENESIS HEALTHCARE, INC., 101 EAST STATE STREET, KENNETT SQUARE PA 19348
James G Carlson director 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Patrick T Blair officer: PRESIDENT 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Caroline Dechert director 580 CALIFORNIA ST., SUITE 1700, SAN FRANCISCO CA 94104
Pavithra Mahesh director 601 LEXINGTON AVE., 53RD FLOOR, NEW YORK NY 10022
Maureen Hewitt director, officer: CEO, President and Director 8950 E. LOWRY BLVD., DENVER CO 80230
Maria Lozzano officer: CORPORATE COO 8950 E. LOWRY BLVD., DENVER CO 80230
Robin Doerr officer: CHIEF SALES AND MKTG. OFFICER 8950 E. LOWRY BLVD., DENVER CO 80230
Melissa Welch officer: CHIEF MEDICAL OFFICER 8950 E. LOWRY BLVD., DENVER CO 80230